To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

To join this study, your doctor would need to confirm that you have an advanced or metastatic solid tumour. This includes specific types of cancer such as ovarian, oesophageal, triple-negative breast cancer, non-small cell lung cancer, small cell lung cancer, head and neck cancer, stomach cancer, cervical cancer, or endometrial cancer. You must have already tried standard treatments, or there might not be any other standard treatments available for your cancer. Your medical team would also need to be able to get a sample of your tumour tissue (either an existing sample or a new biopsy) to help them understand more about your cancer.

There are also some things that might mean you can't take part. For example, if you've already had a different treatment that targets the PTK7 protein for Phase 1a, or other specific related treatments for Phase 1b, you wouldn't be eligible. Some specific types of ovarian cancer or cancers in the nose and throat area (nasopharyngeal tumours) might also prevent you from joining certain parts of the study. Also, if you've recently had certain bowel problems, or issues with fluid build-up in your abdomen that needs frequent draining, you might not be able to participate. Your overall health and how well your organs are working will also be checked.

If you decide to take part in this study, you will receive the study medicine, DAY301. Initially, for the first part of the study, you'll be in a group where the dose of DAY301 will be slowly increased. This is done to find the safest and most effective dose. You will have regular visits to the clinic for check-ups, blood tests, and scans to monitor your health, look for any side effects, and see how the treatment is affecting your cancer. These visits will likely be more frequent at the beginning of the study. Once the safest dose is found, other participants will then receive this dose to gather more information. The total duration of your participation would depend on how well you respond to the treatment and whether you experience any side effects, but patients typically remain on study treatment for several months or longer. Your doctor will explain how often you would need to attend appointments and what tests you would have.